From FLEMMING-: at :-dfhvax.nbi.dk Mon Feb 14 07:22:32 1994 Received: from nbivax for FLEMMING%!at!%dfhvax.nbi.dk by www.ccl.net (8.6.4/930601.1506) id HAA17779; Mon, 14 Feb 1994 07:07:59 -0500 From: Received: from DECNET-MAIL (FLEMMING%!at!%DFHVAX) by nbivax.nbi.dk (PMDF V4.2-13 #5783) id <01H8VKP3IP80AM5DQI _-at-_)nbivax.nbi.dk>; Mon, 14 Feb 1994 13:08:00 +0100 Date: Mon, 14 Feb 1994 13:08:00 +0100 Subject: 2nd Eur. Congr. Pharmaceu. Sci. - Announcement To: chemistry # - at - # ccl.net Message-id: <01H8VKP3MZJMAM5DQI-!at!-nbivax.nbi.dk> X-VMS-To: CCL MIME-version: 1.0 Content-transfer-encoding: 7BIT * * * A N N O U N C E M E N T * * * ------------------------------------------------------------------------------- 2nd European Congress of Pharmaceutical Sciences 29th September - 1st October, 1994 Berlin, Germany ------------------------------------------------------------------------------- The 2nd European Congress of Pharmaceutical Sciences will take place in Berlin, Germany from September 29 to October 1, 1994. The programme will consist of 4 Plenary Trend Lectures and 14 Parallel Symposia on current topics in pharmaceutical sciences to be presented during three days. Short communications and poster sessions will complement the programme. The expected number of participants is approximately 1000. ------------------------------------------------------------------------------- Programme, registration form and further information can be obtained from: Apothekerhaus Carmerstrasse 3 10623 Berlin Germany Tel: (49) 30-3135091 Fax: (49) 30-3123081 ------------------------------------------------------------------------------- Congress Schedule Thursday September 29, 1994 Plenary Lecture J. Drews The evolution of biomedical science and the future of drug design Parallel Symposium 1 Enzymes as targets for drug development A.W. Alberts Recent approaches to cholesterol biosynthesis inhibition R.W. Hartmann Selective inhibition of steroidogenic P450 enzymes: Current status and future perspectives Parallel Symposium 2 Drug targeting D.J.A. Crommelin Targeting of peptide and protein drugs H.P. Merkle New aspects of pharmaceutical dosage forms for controlled drug delivery of peptides and proteins Parallel Symposium 3 Alternative methods to animal experimentation A. Cordier Strategy of using in vitro tests in preclinical safety testing B. Garthoff The use of transgenic animals in drug research Parallel Symposium 4 Pharmaceutical impact on chronic disease therapy R. Paoletti Combined drug therapy and the prevention of cardiovascular diseases J. Urquhart Compliance as a major determinant for the success of chronic drug treatment J.C. Aschoff Physostigmin for cerebellar ataxia's: The phantasies of a clinical neurologist and the real problems in developing a legalized therapeutic system (TTS) Friday September 30, 1994 Plenary Lecture E. De Clercq Trends in drug development for the treatment of AIDS Parallel Symposium 5 Receptor selectivity and drug development J.-C. Schwartz Molecular biology of receptors and drug design T.W. Schwartz Molecular mechanism of agonists and antagonists on neuropeptide receptors Parallel Symposium 6 Computer based methods in pharmaceutical sciences G. Folkers Modelling of ligand-protein interaction complexes as a basis of drug design Y.C. Martin Utility and challenges of 3D databases in new drug discovery Parallel Symposium 7 Overcoming biological barriers C. Laboisse Intestinal cell culture models H. Lennernas Gastrointestinal absorption mechanisms: A comparison between animal and human models Parallel Symposium 8 Non invasive techniques in drug development P. Hartvig PET-illuminating in vivo drug disposition C.G. Wilson Application of gamma scintigraphy to modern dosage form design M. Rudin In vivo magnetic resonance imaging and spectroscopy in pharmacological research: Applications to drug development and profiling Parallel Symposium 9 Pharmacoeconomics - a perspective on drug cost and drug benefit B. Joensson Health economics - what is it about? M.F. Drummond Health economic evaluation and reimbursement of pharmaceuticals G. Kobelt-Nguyen Health economics - an industry perspective Saturday October 1, 1994 Plenary Lectures J. Feijen The impact of biomaterials on pharmacists to drug research Y. Torud Contributions of European pharmacists to drug research Parallel Symposium 10 New approaches in drug synthesis P. Krogsgaard-Larsen Agonists, partial agonists and antagonists at GABA and glutamate receptors in Alzheimer's disease: Chemistry and pharmacology K.T. Wanner Chiral N-acyliminium ions as new tools in the asymmetric synthesis of CNS-active compounds Parallel Symposium 11 Antioxidants and cell protection S. Orrenius Intracellular oxidative processes and cell killing C. Galli Natural antioxidants, lipid peroxidation and platelet/leukocyte functions Parallel Symposium 12 Prediction of drug metabolism D.A. Smith Chemistry and enzymology: Their use in the prediction of human drug metabolism W. Taeschner Prediction of genetic variation of drug metabolism Parallel Symposium 13 Plant metabolites as models for modern drug research W.F. Fleck Benzo[a]naphthacenequinones from microorganisms as models of modern drug research W. Kubelka Constituents of higher plants as models for modern drug research M. Tanker Certain Anatolian plants and their constituents influencing drug disposition Parallel Symposium 14 New opportunities for near infrared (NIR) spectrometry in pharmaceutical and biomedical analysis C. van der Vlies The use of NIR spectrometry in the pharmaceutical control laboratory M. Josefson New opportunities with NIR spectrometry in the analysis of dosage forms R.A. Lodder NIR-Spectrometric imaging ------------------------------------------------------------------------------- The above announcement has been submitted to CCL by: Flemming Steen Jorgensen Associate professor, Ph.D. Royal Danish School of Pharmacy Department of Medicinal Chemistry Universitetsparken 2 DK-2100 Copenhagen Denmark Phone: +45 35 37 08 50 ext. 378 Fax: +45 35 37 22 09 If you need more information, you are welcome to contact me on: flemming {*at*} dfhvax.nbi.dk -------------------------------------------------------------------------------